Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Assets (2016 - 2025)

Rocket Pharmaceuticals' Current Assets history spans 10 years, with the latest figure at $192.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 49.04% year-over-year to $192.7 million; the TTM value through Dec 2025 reached $192.7 million, down 49.04%, while the annual FY2025 figure was $192.7 million, 49.04% down from the prior year.
  • Current Assets for Q4 2025 was $192.7 million at Rocket Pharmaceuticals, down from $227.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $471.8 million in Q1 2021 and bottomed at $192.7 million in Q4 2025.
  • The 5-year median for Current Assets is $341.6 million (2023), against an average of $341.5 million.
  • The largest annual shift saw Current Assets surged 82.27% in 2021 before it crashed 49.04% in 2025.
  • A 5-year view of Current Assets shows it stood at $392.1 million in 2021, then decreased by 7.14% to $364.1 million in 2022, then rose by 3.89% to $378.2 million in 2023, then dropped by 0.01% to $378.2 million in 2024, then plummeted by 49.04% to $192.7 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Current Assets are $192.7 million (Q4 2025), $227.7 million (Q3 2025), and $277.2 million (Q2 2025).